Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.

What Was Tested

This clinical trial looks at Gonadotropin-Releasing Hormone.

Their recently reported finding of rapid bi-exponential elimination of free prostate-specific antigen (PSA) after radical retropubic prostatectomy in patients with moderately elevated PSA levels, which contrasted a very slow, linear elimination of PSA complexed to alpha-1-antichymotrypsin (ACT), prompted them to study whether these elimination rates were applicable for patients selected for castration treatment with very high pretreatment concentrations of PSA in serum.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, men only.

Pretreatment serum was obtained from 21 previously untreated prostate cancer patients due for hormonal treatment with a GnRH-analog.

Samples were also collected during treatment up to a minimum of 24 weeks at 2-week intervals and analyzed with immunofluorometric assays for free PSA (PSA-F), PSA complexed to alpha-1-antichymotrypsin (PSA-ACT), total PSA (PSA-T), and human kallikrein 2 (hK2).

How the Study Was Run

In addition, serum concentrations of hK2, the activator of proPSA, were measured.

What Was Measured

Their recently reported finding of rapid bi-exponential elimination of free prostate-specific antigen (PSA) after radical retropubic prostatectomy in patients with moderately elevated PSA levels, which contrasted a very slow, linear elimination of PSA complexed to alpha-1-antichymotrypsin (ACT), prompted them to study whether these elimination rates were applicable for patients selected for castration treatment with very high pretreatment concentrations of PSA in serum.

PubMed files the paper under topics including Gonadotropin-Releasing Hormone, Predictive Value of Tests, Prostate-Specific Antigen, Prostatectomy, Prostatic Neoplasms, Tissue Kallikreins and alpha 1-Antichymotrypsin.

What This Means in Plain Language

This is a clinical trial of Gonadotropin-Releasing Hormone.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2001 (The Prostate), a journal based in United States.

More context: all human trials.